Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

July 18, 2023

Study Completion Date

July 18, 2023

Conditions
Stage III Non-small Cell Lung CancerUnresectable
Interventions
DRUG

Durvalumab + Oleclumab

Durvalumab + Oleclumab

DRUG

Durvalumab

Durvalumab

DRUG

Durvalumab + Monalizumab

Durvalumab + Monalizumab

Trial Locations (73)

402

Research Site, Taichung

10029

Research Site, New York

10065

Research Site, New York

12002

Research Site, Castellon

13015

Research Site, Marseille

15006

Research Site, A Coruña

17019

Research Site, La Rochelle

17325

Research Site, Gettysburg

17601

Research Site, Lancaster

19104

Research Site, Philadelphia

20007

Research Site, Washington D.C.

20132

Research Site, Milan

20133

Research Site, Milan

21237

Research Site, Rosedale

23230

Research Site, Richmond

26100

Research Site, Cremona

28034

Research Site, Madrid

29010

Research Site, Málaga

29609

Research Site, Brest

31059

Research Site, Toulouse

32804

Research Site, Orlando

33076

Research Site, Bordeaux

33881

Research Site, Winter Haven

35033

Research Site, Rennes

38120

Research Site, Memphis

38138

Research Site, Germantown

40202

Research Site, Louisville

40503

Research Site, Lexington

46014

Research Site, Valencia

48121

Research Site, Ravenna

53100

Research Site, Siena

57105

Research Site, Sioux Falls

59037

Research Site, Lille

61363

Research Site, Chiayi City

67065

Research Site, Strasbourg

67214

Research Site, Wichita

68510

Research Site, Lincoln

69004

Research Site, Lyon

69495

Research Site, Pierre-Bénite

69677

Research Site, Bron

70433

Research Site, Covington

70809

Research Site, Baton Rouge

75701

Research Site, Tyler

84112

Research Site, Salt Lake City

87042

Research Site, Limoges

90127

Research Site, Palermo

91010

Research Site, Duarte

92801

Research Site, Anaheim

94010

Research Site, Créteil

95125

Research Site, Catania

95825

Research Site, Sacramento

98405

Research Site, Tacoma

06510

Research Site, New Haven

06516

Research Site, West Haven

97227-1191

Research Site, Portland

T6G 1Z2

Research Site, Edmonton

M5G 2M9

Research Site, Toronto

H4A 3J1

Research Site, Montreal

06189

Research Site, Nice

Unknown

Research Site, Hong Kong

Research Site, Jordan

Research Site, Kowloon

81-519

Research Site, Gdynia

90-153

Research Site, Lodz

90-242

Research Site, Lodz

1400-038

Research Site, Lisbon

1500-650

Research Site, Lisbon

4099-001

Research Site, Porto

4200-072

Research Site, Porto

06008

Research Site, Badajoz

08035

Research Site, Barcelona

08041

Research Site, Barcelona

08916

Research Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY